Martina Diekmann
Directeur Général chez vivitite LLC
Profil
Martina Diekmann is currently the Chief Executive Officer at Mytide Therapeutics, Inc. and the President, Chief Executive Officer & Director at vivitite LLC.
She was formerly the Chief Executive Officer at New England Peptide, Inc. She holds a doctorate degree from the University of Bonn.
Postes actifs de Martina Diekmann
| Sociétés | Poste | Début |
|---|---|---|
vivitite LLC
 vivitite LLC Medical SpecialtiesHealth Technology Part of Biosynth Holding AG, vivitite LLC is a provider of custom peptides, antibody services, and catalog products for the life science and biotech industry. The company is based in Gardner, MA, with significant operations in KY. Vivitide was founded in 2019, and Martina Diekmann has been the CEO of the company since 2020. Committed to outstanding quality and customer service, vivitide provides a broad portfolio of custom peptide synthesis services, custom antibodies, catalog peptides, and biochemicals to academia, pharmaceutical, biotech, and diagnostic companies worldwide. Vivitite LLC was acquired by Biosynth Carbosynth, part of Biosynth Holding AG from April 08, 2022 on March 17, 2022. | Directeur Général | 01/02/2020 |
Mytide Therapeutics, Inc.
 Mytide Therapeutics, Inc. Packaged SoftwareTechnology Services Mytide Therapeutics, Inc. is a peptide and biopolymer manufacturing and computational biology company based in Massachusetts. Mytide's focus is on eliminating the time-consuming and labor-intensive chemical and screening processes that prevent innovative therapeutics from reaching the clinic. The American company's quick-turn manufacturing technology, combined with AI-enabled predictive analytics, provides access to a novel peptide space for the discovery and therapeutic manufacturing of difficult-to-make natural and non-natural peptide and peptide conjugates. The company was founded by Dale Thomas and has been led by CEO Martina Diekmann since 2023. | Directeur Général | 30/03/2023 |
Anciens postes connus de Martina Diekmann
| Sociétés | Poste | Fin |
|---|---|---|
New England Peptide, Inc.
 New England Peptide, Inc. Chemicals: Major DiversifiedProcess Industries New England Peptide, Inc. designs and manufactures peptides, polyclonal antibodies, and monoclonal antibodies for drug and vaccine discovery organizations. Its products include TrypTides, bioactive peptides, amino acids and resins, peptide synthesis accessories, ME Kit Exosome isolation, SISCAPA assay reagents, and TrypRaws. The company was founded by Samuel A. Massoni and Jennifer L. Massoni in 1998 and is headquartered in Gardner, MA. | Directeur Général | - |
Formation de Martina Diekmann
| University of Bonn | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
New England Peptide, Inc.
New England Peptide, Inc. Chemicals: Major DiversifiedProcess Industries New England Peptide, Inc. designs and manufactures peptides, polyclonal antibodies, and monoclonal antibodies for drug and vaccine discovery organizations. Its products include TrypTides, bioactive peptides, amino acids and resins, peptide synthesis accessories, ME Kit Exosome isolation, SISCAPA assay reagents, and TrypRaws. The company was founded by Samuel A. Massoni and Jennifer L. Massoni in 1998 and is headquartered in Gardner, MA. | Process Industries |
vivitite LLC
vivitite LLC Medical SpecialtiesHealth Technology Part of Biosynth Holding AG, vivitite LLC is a provider of custom peptides, antibody services, and catalog products for the life science and biotech industry. The company is based in Gardner, MA, with significant operations in KY. Vivitide was founded in 2019, and Martina Diekmann has been the CEO of the company since 2020. Committed to outstanding quality and customer service, vivitide provides a broad portfolio of custom peptide synthesis services, custom antibodies, catalog peptides, and biochemicals to academia, pharmaceutical, biotech, and diagnostic companies worldwide. Vivitite LLC was acquired by Biosynth Carbosynth, part of Biosynth Holding AG from April 08, 2022 on March 17, 2022. | Health Technology |
Mytide Therapeutics, Inc.
Mytide Therapeutics, Inc. Packaged SoftwareTechnology Services Mytide Therapeutics, Inc. is a peptide and biopolymer manufacturing and computational biology company based in Massachusetts. Mytide's focus is on eliminating the time-consuming and labor-intensive chemical and screening processes that prevent innovative therapeutics from reaching the clinic. The American company's quick-turn manufacturing technology, combined with AI-enabled predictive analytics, provides access to a novel peptide space for the discovery and therapeutic manufacturing of difficult-to-make natural and non-natural peptide and peptide conjugates. The company was founded by Dale Thomas and has been led by CEO Martina Diekmann since 2023. | Technology Services |
